December 9, 2013; 5:30 - 8:30pm
Downtown Harvard Club, One Federal Street, 38th Floor, Boston, MA 02110
"Can you safely market your products in Russia?
The status of IP protection in Russia."
With Donald Townsend, Regional Intellectual Property Rights (IPR) Attaché for Russia, CIS, and Georgia for the U.S. Foreign Commercial Service/U.S. Patent and Trademark Office (USPTO)
and Mark Henry, CEO of Bach Pharma
Monday, December 9th, 5:30-8:30pm
Harvard Club - Downtown, One Federal Street, 38th Floor, Boston, MA
Members: $40 Non-Members: $45
Donald Townsend will provide an overview of the USPTO IPR Attaché Program, the general IP environment in Russia, including legislative developments over the past year, and the challenges of IPR enforcement in the region. In addition, pharmaceutical industry specific topics will be touched upon, including counterfeit medicines, patent linkage and data exclusivity issues affecting the innovative pharmaceutical industry in Russia. Further, trademark and copyright industry issues will be discussed, including the fight against piracy and counterfeit products. Mark Henry will discuss how the current legal and business climate in Russia affects the ability of foreign business to commercialize their IP-protected products/technology in Russia
About the speakers:
Donald E. Townsend, Jr. is the regional U.S. Intellectual Property Rights Attaché to Russia, the CIS and Georgia, dealing with all manner of intellectual property issues, including patents, trademarks, copyrights, and enforcement issues thereof. Prior to joining government service, Mr. Townsend was a practicing registered U.S. patent attorney specializing in international intellectual property matters, primarily in the U.S. and Asia. With a chemical educational background, Mr. Townsend specialized in chemical and pharmaceutical patent matters, as well as related trademark and copyright issues concerning same, contracts and licensing. Mr. Townsend received a Bachelor of Science degree in chemistry, and a Juris Doctorate (J.D.) law degree.
Mark Henry is a founder of Bach Pharma, an International Irish Trading company for distribution and licensing of pharmaceutical products worldwide. Bach’s drug platform is based on a medical technology Mark discovered in Russia. Mark is the CEO, CFO, President, and a member of the Board of Directors at Bach since its inception in 2001. He is also a Planning Commission Member, U.S.-Russian Scientific Exchange Forum, U.S. State Department, National Institutes of Health Foundation, established by the Office of the President in 2010, and was appointed by the NIH and US Secretary of State and The World Health Organization to help prepare for the November 2011 Conference held at the Russian Academy of Sciences in Moscow.
<< All Past Events